Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience

被引：0
|
作者：
Matrana, Marc Ryan
Shetty, Aditya V.
Atkinson, Bradley J.
Xiao, Lianchun
Corn, Paul G.
Millikan, Randall E.
Jonasch, Eric
Tannir, Nizar M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas Houston, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4615
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Berger, Raanan
    Carducci, Michael Anthony
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience
    Lalani, A-K.
    Li, H.
    Heng, D.
    Wood, L.
    Kalirai, A.
    Bjarnason, G.
    Sim, H-W.
    Kollmannsberger, C. K.
    Kapoor, A.
    Hotte, S. J.
    Vanhuyse, M.
    Czaykowski, P.
    Reaume, M. N.
    Soulieres, D.
    Venner, P.
    North, S.
    Basappa, N.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [43] Prognostic factors and validation of prognostic nomograms in patients (pts) treated with three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC): Results from an Italian survey
    Iacovelli, Roberto
    Milella, Michele
    Santoni, Matteo
    Di Lorenzo, Giuseppe
    Ortega, Cinzia
    Sabbatini, Roberto
    Ricotta, Riccardo
    Lorusso, Vito
    Messina, Caterina
    Atzori, Francesco
    Zucali, Paolo A.
    Cinieri, Saverio
    Mosca, Alessandra
    Verzoni, Elena
    Primi, Francesca
    Baratelli, Chiara
    Cortesi, Enrico
    Carteni, Giacomo
    Sternberg, Cora N.
    Procopio, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [44] PROGNOSTIC FACTORS AND VALIDATION OF PROGNOSTIC NOMOGRAMS IN PATIENTS (PTS) TREATED WITH 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS FROM AN ITALIAN SURVEY
    Iacovelli, R.
    Rizzo, M.
    Lorusso, V.
    Atzori, F.
    Zucali, P. A.
    Sacco, C.
    Boccardo, F.
    Valduga, F.
    Massari, F.
    Procopio, G.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 276 - 277
  • [45] Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Roubinov, Keren
    Berger, Raanan
    Carducci, Michael Anthony
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [46] Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy
    Wood, L.
    Bukowski, R. M.
    Dreicer, R.
    Elson, P.
    Garcia, J. A.
    Gilligan, T.
    Mekhail, T.
    Rini, B. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Single centre experience and patients characteristics treated with targeted therapy for metastatic renal cell carcinoma
    Zubaidah, N.
    Othman, U.
    Tan, S. Y. X.
    Basheer, A. A. M.
    Nasuha, N. Azam
    [J]. BJU INTERNATIONAL, 2023, 132 (SUPP2) : 30 - 31
  • [48] Outcomes of sunitinib therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) with poor risk features
    Barroso-Sousa, Romualdo
    Munhoz, Rodrigo Ramella
    Fonseca, Leonardo Gomes
    de Sousa Fede, Angelo Bezerra
    Marques Linck, Rudinei Diogo
    Venchiarutti Moniz, Camila Motta
    Mak, Milena Perez
    Souza, Ciro Eduardo
    Hoff, Paulo M.
    Dzik, Carlos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [49] The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).
    Fay, Andre Poisl
    de Velasco, Guillermo
    Gray, Kathryn P.
    Ho, Thai Huu
    Song, Jiaxi
    Kapur, Payal
    Albiges, Laurence
    McDermott, David F.
    Heng, Daniel Yick Chin
    Brugarolas, James
    Choueiri, Toni K.
    Signoretti, Sabina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [50] Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study
    Nagyivanyi, Krisztian
    Budai, Barna
    Gyergyay, Fruzsina
    Kuronya, Zsofia
    Biro, Krisztina
    Geczi, Lajos
    [J]. CLINICAL DRUG INVESTIGATION, 2019, 39 (06) : 577 - 583
12345